Publication July 23, 2026

TB-500 Studied With BPC-157 in Rat Achilles Tendon Healing

Drafted by an automated content engine from FDA, PubChem, ClinicalTrials.gov, NIH DSLD, and Open Beauty Facts data.

A new study titled "Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study" was published on July 23, 2026. The publication appeared in the journal Joint Diseases and Related Surgery. It examines TB-500 alongside BPC-157 in a rat model of Achilles tendon healing, using histopathological and biomechanical assessment methods.

TB-500 remains classified as an unapproved research compound and is not authorized for human therapeutic use. This publication represents a peer reviewed contribution to the existing research literature on tendon healing agents studied in animal models.

No specific outcomes, measurements, or efficacy conclusions from the study are detailed in this brief beyond confirming the publication's title, journal, and date. Those seeking the full findings should consult the original source directly.

Readers interested in the broader research context surrounding TB-500 can refer to the compound overview for additional background.

See the full tb-500 overview

Source: https://pubmed.ncbi.nlm.nih.gov/42542926/